Key result
Genotype-guided antiplatelet and statin therapies show increasing evidence for improving personalized cardiovascular care.
Why the study?
Advances in pharmacogenomics have paved the way for personalized medicine, warranting a review of the background, rationale, and evidence in cardiovascular medicine.
This review highlights the growing role of pharmacogenomics in cardiovascular medicine, particularly for guiding antiplatelet therapy and understanding statin-associated muscle symptoms.
Does not yet support routine genotype-guided antiplatelet or statin therapy; leaves open whether pharmacogenomics improves cardiovascular outcomes.
PURPOSE OF REVIEW: Advances in pharmacogenomics have paved the way for personalized medicine. The purpose of this review is to summarize the background, rationale, and evidence for pharmacogenomics in cardiovascular medicine. RECENT FINDINGS: Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary interventions. Additionally, there is increasing evidence supporting the association of certain genetic variants and risk of statin associated muscle symptoms. Furthermore, germline genetic variation is being used as a biomarker to target patients with specific therapy. SUMMARY: Pharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of novel drug therapies for cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2023) conducted a review in Cardiovascular disease. Pharmacogenomics was evaluated. Genotype-guided approaches for antiplatelet therapy and statin use show increasing evidence for improving personalized patient care in cardiovascular medicine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: